



## CLINICAL STUDY VALIDATES AXENYA DIABETES PLATFORM

Montevideo, Uruguay, March 30th, 2021. AXENYA, a Latin-American digital therapeutics start-up company, announces that it has finished a clinical study in 60 patients suffering Diabetes Type 1 and Type 2. Confirming the company's commitment to basing its development in rigorous clinical outcomes, Axenya partnered with Dr. Adrian Proietti, a well-known Latin American endocrinologist, with extensive background in the application of technology to the monitoring and treatment of diabetes mellitus.

The study demonstrated the Axenya Diabetes Program participants achieved meaningful outcomes three months after beginning the program, including:

- Reducing average estimated Hemoglobin A1c by 1 percentage point for all study participants, reaching the American Diabetes Association recommendation of 7%;
- An average reduction of 1.8 percentage points in Type 2 patients, which started with a baseline A1C of 8.8%;
- An average decrease of 13 mcg/ml on average glucose for Type 1 patients and of 51 mcg/ml for Type 2 patients;
- Meaningful increases in patients' compliance with treatment; and,
- Meaningful increases in patients' perception about like habits, feedback learning, control and overall trust in their doctors and their treatment.

Patients also reported an overall Net Promoter Score of 62 points. This, according to a recent study published by the Temkin group, compares to an average of 27 points for the healthcare industry.

The study took place from August 2020 through December 2020, meaning participants maintained engagement, and achieved results, throughout the COVID-19 public health emergency.

"These studies confirm Axenya's commitment with staying at the forefront in the region in terms of research-based digital therapies and at par with the world's most advanced platforms to treat chronic conditions", said Dr. Esteban Rubin, Axenya's Chief Medical Officer.

"Axenya has significantly expanded our medical toolkit", said Dr. Adrian Proietti, Chief Investigator of the study. "Our patient-base showed clear objective and subjective improvements. Their clinical data is undoubtedly better and their engagement with their condition has also shown significant improvement. These results undoubtedly show the potential of the technology to reduce the clinical and psychological burden of the disease"

Full study results will be published later this year.

## ABOUT AXENYA

Axenya is a digital therapeutic startup company dedicated to empowering Latin American doctors and patients to plug into the future of medicine. Axenya provides state-of-the-art software and hardware that expand physicians' toolboxes, enhance the efficiency of healthcare delivery and make medicine more personalized and precise. Axenya enables better care, drives measurable outcomes and enriches the doctor-patient relationship in innovative, profound and meaningful ways.